Download the Report
Mobile
Disruption by Collaboration
Linda Higgins, Senior Vice President of External Innovation at Gilead, explains our collaborative approach to research and development.
RESEARCH AND DEVELOPMENT
Focused on
Innovation
A new model for collaboration and partnership.
Two Companies.
One Goal.
With our transformative partnership, Gilead and Galapagos are expanding and accelerating our research and commercialization programs to support unmet medical needs.
Balance:
Strive to Be Fast-to-Market and Best-in-Class
Drive:
Entrepreneurial Spirit Meets Established Legacy of Success
Care:
Commitment to Patients
Addressing Unmet
Medical Needs
A Pipeline of Possibilities
To us, the impossible is simply what hasn’t been achieved yet. Gilead’s research and development program is focused on what’s next, integrating internal and external research to build a robust pipeline.
Taking It to the Next Level
Through the years, Gilead’s research programs have helped propel science forward. Now, with the creation of our External Innovation Center, we’re working more closely with partners to bring the best learnings to our teams as we aim to bring 10+ new transformative therapies to patients in the next 10 years. In 2019, we established more than 17 strategic partnerships and licensing deals to keep the momentum going.
"Together with our industry’s most-respected colleagues, Gilead is pushing the limits of its R&D capabilities, putting patients and their quality of life front and center."
Linda Higgins, SVP of External Innovation at Gilead
We're Ready for What's Next
The work is already underway. Read Gilead’s 2019 Year in Review to learn more.